Prevalence of Common Driver Mutations in Advanced Adenocarcinoma of Lung in a Tertiary Hospital of Nepal
DOI:
https://doi.org/10.3126/jcmsn.v20i4.71614Keywords:
driver gene mutation, EGFR mutation, lung adenocarcinomaAbstract
Background
Molecular testing of lung adenocarcinoma has become standard in clinical practice because the studies have shown that the use of targeted therapies increases the overall survival and quality of life in these patients. The primary aim of this study is to see the prevalence of common driver gene mutations (DGM) in advanced adenocarcinoma of lung in Nepalese population.
Methods
Retrospective collection of information regarding age, gender, and DGM in advanced lung adenocarcinoma was gathered covering the period from January 2022 to July 2023. Data was analyzed by using SPSS-20 using descriptive statistical tools in terms of frequency and percentage.
Results
Among 112 patients, 25% had Epidermal Growth Factor Receptor (EGFR) mutation, with exon 19 deletion being more prevalent (17 patients) compared to exon 21 L858R point mutation (nine patients). The occurrence of EGFR mutation was higher in males (14.29%) than in females (10.71%). Anaplastic Lymphoma Kinase (ALK)translocation was identified in six patients, while only one patient exhibited ROS1 rearrangement. Approximately 3% of patients did not undergo successful DGM tests due to insufficient tissue in the biopsy sample.
Conclusions
A quarter of patients diagnosed with advanced lung adenocarcinoma carry EGFR mutations. Sufficient tissue sampling is necessary to conduct driver mutation tests effectively.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
This license enables reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator.